

WE CLAIM:

1. A method for treating and/or preventing hypergastrinemia comprising administering to a patient in need thereof a therapeutically effective amount of an antigastrin immunogenic composition, comprising a G17 or G34 peptide fragment or a combination thereof linked by an amino acid spacer to an immunogenic carrier.
2. The method of claim 1, wherein the spacer is a Ser peptide spacer.
3. The method of claim 1, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.
4. The method of claim 1, wherein the hypergastrinemia is associated with pernicious anemia or administration of a substance which results in increased gastrin levels.
5. A method for treating and/or preventing hypergastrinemia comprising administering to a patient in need thereof a therapeutically effective amount of anti-G17 antibodies.
6. The method of claim 5, wherein the hypergastrinemia is associated with pernicious anemia or administration of a substance which results in increased gastrin levels.
7. A method for treating tumors associated with hypergastrinemia comprising administering to a gastrin related tumor bearing patient an anti-gastrin immunogen or anti-gastrin antibodies.
8. Use of a therapeutically effective amount of an antigastrin immunogenic composition, comprising a G17 or G34 peptide fragment or a combination thereof linked by an amino acid spacer to an immunogenic carrier in the

preparation of a medicament for treating and/or preventing hypergastrinemia in a patient.

9. Use according to claim 8, wherein the spacer is a Ser peptide spacer.
10. Use according to claim 8, wherein the immunogenic carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.
11. Use according to claim 8, wherein the hypergastrinemia is associated with pernicious anemia or administration of a substance which results in increased gastrin levels.
12. Use of a therapeutically effective amount of anti-G17 antibodies in the preparation of a medicament for treating and/or preventing hypergastrinemia in a patient.
13. Use according to claim 12, wherein the hypergastrinemia is associated with pernicious anemia or administration of a substance which results in increased gastrin levels.
14. Use of an anti-gastrin immunogen or anti-gastrin antibodies in the preparation of a medicament for treating tumors associated with hypergastrinemia in a gastrin related tumor bearing patient.

ADD B27